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Abstract
 
Streptococcus pneumoniae
 
 is the most common cause of bacterial meningitis of high mortality and
morbidity. Neurological sequelae include paralysis, mental retardation, and learning disorders.
In humans, neurons of the hippocampus undergo apoptosis as a result of meningitis. Phosphati-
dylcholine (PtdCho) is an essential component of mammalian cell membranes and PtdCho
deficiency, either due to chemicals or altered nutrition, leads to apoptosis, especially in hippo-
campal neurons. We show that apoptosis of a variety of brain cells after pneumococcal infec-
tion arises from inhibition of PtdCho biosynthesis, the first such activity described for a bacte-
rium. Apoptosis inhibitors did not prevent the bacterial-dependent inhibition of PtdCho
biosynthesis. Supplementation with exogenous lyso-phosphatidylcholine prevents cell death
and treatment of mice with cytidine diphosphocholine attenuates hippocampal damage during
meningitis, even after the onset of infection. We conclude that bacterial inhibition of PtdCho
biosynthesis activates an apoptotic cascade that is a causative event in pathogenesis and amenable
to therapeutic intervention.
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Introduction
 
Streptococcus pneumoniae
 
 remains one of the most common
causes of bacterial meningitis and despite effective antimi-
crobial therapy, continues to be associated with high mor-
tality and morbidity (1). About one third of the survivors,
especially children, experience neurological sequelae including
deafness, mental retardation, focal neurologic deficits, and
cognitive impairment (2–4). Defects in learning and memory
result from neuronal apoptosis in the hippocampus (5), a
pathological process arising from bacterial induction of two
equally important mechanisms, each with a different trigger
and different apoptotic pathway. Caspase-dependent apoptosis
accounts for about half of the neuronal loss in the hippo-
campus during meningitis as evidenced by partial rescue in
animals treated with the broad spectrum caspase inhibitor
z-VAD-fmk (6). Initiation of caspase-dependent neuronal
death critically depends on leukocyte-derived products
because damage to neurons can be attenuated by anti-CD18
antibody and recapitulated in vitro by inflamed, leukocyte-
containing cerebrospinal fluid, but not cell-free fluid. In
the second apoptotic process, the bacterium itself induces
hippocampal neuronal death directly (7, 8). This process is
not associated with the activation of caspases 1–10 and is
not inhibited by z-VAD-fmk in vitro or in vivo. Rather,
apoptosis is attributable to damage to mitochondria by two
pneumococcal toxins, pneumolysin and H
 
2
 
O
 
2
 
, leading to
the release of apoptosis-inducing factor (AIF) from mito-
chondria and large-scale DNA fragmentation. Injection of
cells with anti-AIF antiserum or treatment with a calcium
chelator blocks AIF release and neuronal cell death (7). In
experimental pneumococcal meningitis, pneumolysin colo-
calizes with apoptotic neurons of the hippocampus, and infec-
tion  with pneumococci unable to produce pneumolysin
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and H
 
2
 
O
 
2 
 
causes about half as much damage as infection
with wild-type strains. Recent evidence in support of the
coexistence of two apoptotic processes during pneumococ-
cal infection comes from studies on dendritic cells (9),
which demonstrate bacterial toxin–induced, caspase-inde-
pendent apoptosis and host response–derived, caspase-depen-
dent apoptosis. Such a multiplicity of apoptotic triggers
complicates efforts to deploy apoptosis inhibitors to im-
prove neuronal survival after meningitis, a setting where a
single or at least dominant salvage treatment would be
highly desirable.
Phosphatidylcholine (PtdCho) is a major component of
eukaryotic cell membranes. Its biosynthesis occurs mainly
via the cytidine diphosphocholine (CDP-choline) pathway
and involves three enzymatic reactions (Fig. 1; references
10 and 11). The rate-limiting step in this pathway is the
second step, the CTP:phosphocholine cytidylyltransferase
(CCT)-catalyzed reaction, and the activity of this enzyme
is highly regulated (12). Induction of apoptosis by inhibi-
tion of the enzymes CCT or choline phosphotransferase
(CPT) is a mechanism of action of the anticancer drugs
ET-18-OCH
 
3 
 
(13), HexPC (14), camptothecin and etopo-
side (15), the cytotoxic agents farnesol and chelerythrine
(15), and the short-chain ceramides (16, 17). Choline dep-
rivation, leading to PtdCho deficiency, is also known to
trigger apoptosis in neurons (18). Here we report that the
apoptosis of neurons and microglia triggered during pneu-
mococcal infection appears to involve the inhibition of
PtdCho biosynthesis as a determining factor, the first ex-
ample of this type of toxicity induced by a bacterium.
 
Materials and Methods
 
Bacterial Cell Culture.
 
The following isogenic strains of pneu-
mococci were used: D39 capsular type 2 and R6, its nonencapsu-
lated derivative (provided by A. Tomasz, Rockefeller University,
New York, NY), the pneumolysin
 
  
 
mutant 
 
plnA
 
  
 
(provided by
D. Briles, University of Alabama, Birmingham, AL), the pyruvate
oxidase mutant 
 
spxB
 
  
 
deficient in H
 
2
 
O
 
2 
 
production (19), the
 
plnA
 
 
 
/spxB
 
  
 
double mutant (6), and the adherence-defective
 
cbpA
 
  
 
mutant (20). T4 capsular serotype 4 and its nonencapsu-
lated derivative T4R were also tested. Bacteria were grown over-
night in a casein hydrolysate medium supplemented with yeast
extract and appropriate antibiotics for maintaining mutant selec-
tion. The bacterial inoculum (10
 
7 
 
bacteria/ml) was adjusted pho-
tometrically (OD, 620 nm), centrifuged, washed with PBS, and
then resuspended in cell culture media. For some experiments,
bacteria were replaced by 1 
 
 
 
g/ml recombinant pneumolysin
(provided by T. Mitchell, University of Glasgow, Glasgow, UK)
or 1 mM hydrogen peroxide (Sigma-Aldrich).
 
Cell Culture.
 
A human microglial cell line (HMC; provided
by C.A. Colton, Georgetown University, Washington, DC) that
expresses most markers common to primary human microglia was
cultured as described previously (7). Primary human microglia,
primary rat hippocampal neurons (21), A549 human lung epithe-
lial cell line (American Type Culture Collection [ATCC]),
RBEC6 rat brain endothelial cell line (22), or PC12 rat pheochro-
mocytoma cell line (ATCC) were seeded in 60-mm culture dishes
(4–5 
 
  
 
10
 
5 
 
cells) and cultured in DMEM medium containing 5%
fetal calf serum at 37
 
 
 
C in a humidified atmosphere of 5% CO
 
2
 
.
Cells were infected 48 h later at a confluency of 
 
 
 
80% with dif-
ferent strains of 
 
S. pneumoniae
 
 for 3–4 h as indicated. Cell number
and viability were assessed by counting on a hemocytometer, try-
pan blue exclusion, lactate dehydrogenase (LDH) release, and
staining by acridine orange and ethidium bromide.
 
Metabolic Labeling.
 
12 h before infection, 4–5 
 
  
 
10
 
5 
 
cells
were cultured in choline-free media. At the time of infection,
[
 
methyl-
 
3
 
H]choline chloride (1 
 
 
 
Ci/ml, 80 Ci/mmol; American
Radiolabel Chemicals Inc.) and unlabeled choline (4 
 
 
 
M final
concentration/dish) were added without change of media during
the 4 h of infection. After the infection, cells were scraped,
washed twice with ice-cold PBS, and centrifuged, and the cell
pellet was stored at 
 
 
 
20
 
 
 
C. Extraction of lipids was performed
according to Bligh and Dyer (23). Incorporation of [
 
methyl-
 
3
 
H]choline into PtdCho was measured by quantification of total
radioactivity in the lipid extract using scintillation counting be-
cause 
 
 
 
95% of the radiolabel was identified as PtdCho. Separa-
tion of the water soluble [
 
methyl
 
-
 
3
 
H]choline metabolites was
performed by spotting aliquots of the upper phase onto pread-
sorbent silica gel thin layer chromatography plates, which were
developed in 95% ethanol/2% NH
 
4
 
OH (1:1, vol/vol). Identifi-
cation of radiolabeled choline, phosphocholine, and CDP-cho-
line was made by comigration with authentic standards. After
chromatography, the samples were scraped from the plates and
dissolved in water, and radioactivity was quantified by scintilla-
tion counting.
 
Apoptosis Assays.
 
Morphological changes were documented
by light microscopy and uptake of acridine orange and ethidium
bromide. Apoptotic cells were detected by flow cytometric anal-
ysis (FACSCalibur™; Becton Dickinson) of cells stained for
phosphatidylserine exposed on the plasma membrane. Cells were
treated with fluorescein-conjugated annexin V and propidium
iodide according to the manufacturer’s instructions (Becton
Dickinson), and then analyzed by FACS
 
® 
 
using a 488-nm argon
ion laser. For analyzing mitochondrial transmembrane potential
(
 
  
 
m), cells were incubated with 5,5
 
 
 
,6,6
 
 
 
-tetrachloro-1
 
 
 
1,3,3
 
 
 
-
tetrahylbenzimidazolcarbocyanine-iodide (JC-1) according to the
manufacturer’s instructions (Molecular Probes). Emitted fluores-
cence was measured by FACS
 
® 
 
analysis.
Antibodies to activated caspase 3 and AIF (BD Biosciences),
cytochrome C (Santa Cruz Biotechnology, Inc.), and Lamin B
(Oncogene Research Products) were used in Western blot analy-
ses to characterize apoptotic cells. 0.5–10
 
7 
 
cells were harvested at
80% confluence and extraction of the nucleus was performed as
described elsewhere (24).
For inhibition of apoptosis, cells were treated 30 min before
infection with either 80 
 
 
 
M 
 
l
 
-
 
 
 
-lysophosphatidylcholine
from egg (Avanti Polar Lipids, Inc.), 60 
 
 
 
M caspase inhibitor
Z-Val_Ala_ASP(Ome)-FMK (ZVAD-fmk; Enzyme Systems
Products), 25 
 
 
 
M calpain inhibitor 1 
 
N
 
-acetyl-Leu-Leu-Nle-
CHO (ALLN; Enzyme Systems Products), 50 
 
 
 
M fumonisin B
 
1
Figure 1. The Kennedy pathway. The CDP-choline pathway is cata-
lyzed by choline kinase (CK), CTP:phosphocholine cytidylyltransferase
(CCT), and CDP-choline:1,2-diacylglycerol cholinephosphotransferase
(CPT; reference 10). 
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(Sigma-Aldrich), or 5 
 
 
 
M Ca
 
2
 
-chelator BAPTA-AM (Molecular
Probes). For some experiments, 100 
 
 
 
M citicoline (BIOMOL
Research Laboratories, Inc.) was applied to the cells for 24 h be-
fore infection.
 
Inhibition of Apoptosis In Vivo.
 
4–5-wk-old C57BL/6 mice
(The Jackson Laboratory) were anesthetized and infected via
lumbar puncture with either saline (
 
n 
 
  
 
6) or 10
 
4 
 
strain D39
pneumococci (
 
n 
 
  
 
13) in 20 
 
 
 
l as described previously (25). Six
mice received 500 mg/kg citicoline intraperitoneally 24 h before
infection and via lumbar puncture at the time of infection. A sec-
ond set of five mice per group received citicoline via lumbar
puncture only at 6 h after infection. Mice receiving citicoline
alone showed no hippocampal apoptosis and citicoline did not af-
fect bacterial growth. Mice were killed at 24 h and perfused trans-
cardially with 3% paraformaldehyde and 0.1% glutaraldehyde
(Sigma-Aldrich) in 0.1 M cacodylate buffer (Ted Pella, Inc.), pH
7.4, adjusted with sucrose to 300 mOsm. Brains were removed,
postfixed overnight in 10% formalin, embedded in paraffin, sec-
tioned (5 
 
 
 
m), deparaffinized, rehydrated, and stained. Hematox-
ylin and eosin stain was used to visualize and measure the area of
dentate gyrus of the hippocampus using the NIH Scion Image
Beta 4.02 software. To quantitate apoptosis, TUNEL staining
(five sections per mouse) was performed (Apop Tag Plus Peroxi-
dase In Situ Apoptosis Detection Kit; Serologicals Corp.). All ex-
periments were performed in compliance with National Institutes
of Health (NIH) and institutional guidelines.
 
Statistical Analysis.
 
Statistical analysis was performed using
SigmaStat software version 2.03. Data are presented as mean 
 
 
 
SD or 
 
  
 
SEM as indicated in the figure legends. Differences be-
tween groups were evaluated using the Student’s 
 
t
 
 test or the
Mann-Whitney rank sum test unless otherwise stated. P 
 
  
 
0.05
was considered an indication of statistical significance.
 
Results
 
Infection with S. pneumoniae Inhibits PtdCho Biosynthesis.
 
Microglia are an effective model cell type to study brain
cell injury because they proliferate well in vitro and their
metabolism is tightly coupled to neuronal activity (26). Ex-
posure of a human microglial cell line (7) to 
 
S. pneumoniae
 
D39 or its unencapsulated derivative R6 for 4 h (multiplic-
ity of infection, 30 bacteria/human cell) induced apoptosis
as measured by markers of cell death such as translocation
of phosphatidylserine and loss of mitochondrial membrane
potential (Fig. 2 A), cleavage of lamin B, and release of cy-
tochrome C and AIF into the cytoplasm (not depicted).
To determine if infection with 
 
S. pneumoniae
 
 influenced
PtdCho biosynthesis, the cell line and primary microglia
were labeled with [
 
methyl-
 
3
 
H]choline for 4 h and chal-
lenged with 
 
S. pneumoniae
 
 D39 or R6. Chromatographic
separation of the phospholipids showed that the majority of
the label was incorporated into PtdCho (unpublished
data). The ratio of phosphocholine to CDP-choline was
5:1, in agreement with previous studies in neurons after
short-term labeling (27). Significant inhibition of [
 
methyl-
 
3
 
H]choline incorporation into PtdCho occurred upon in-
fection with D39 (41.2 
 
  
 
6% inhibition) or R6 (67.4 
 
 
 
8% inhibition) as compared with the uninfected cells (Fig.
2 B). 
 
S. pneumoniae
 
 T4 and its unencapsulated derivative
T4R yielded similar results of 56.4 
 
  
 
9 and 55.4 
 
  
 
8% in-
hibition, respectively. This effect was not the result of de-
pletion of nutritional choline because [
 
methyl-
 
3
 
H]choline
was used in 40-fold excess over that which is needed by
cells and pneumococci together. Furthermore, bacteria in-
corporated only 2.4% of the total label into CDP-choline
and this amount was rendered negligible in additional anal-
yses by washing away the bacteria from adherent microglia
before quantitation of [
 
3
 
H]choline incorporation into host
cellular products.
Exposure of other cell types to R6, including a neuronal-
type cell line (PC12), an epithelial cell line (A-549), and a
Figure 2. Inhibition of PtdCho biosynthesis by S. pneumoniae induces
apoptosis. (A) FACS® analysis of mitochondrial membrane potential of
control (left) and infected (middle and right) microglia. Dot plots show
side scatter signals (x axis) versus fluorescence intensity (y axis) for microglia
cells. Shift of fluorescence of JC-1 from 590 (FL2) to 530 nm (FL1) indi-
cates membrane depolarization. Analysis representative of six independent
experiments. (B) Rate of PtdCho biosynthesis. [methyl-3H]choline–labeled
human primary microglia (black bars) or cultured cells (white bars) were
infected with 2   107 cells of strain D39 or R6 pneumococci for 4 h. PtdCho
synthesis was measured by scintillation counting and values were normal-
ized to the protein concentration of the sample. Values are mean   SE of
10 duplicate experiments. *, P   0.05. (C) Distribution of [methyl-3H]choline
incorporation into water-soluble choline intermediates in microglia. *, P  
0.05. Total cpm incorporated were 292,536   68,812. Bacteria alone in-
corporated 13,410   4,797 (4.5%). 
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brain endothelial cell line (RBE6), also showed an inhibi-
tion of incorporation of label into PtdCho, but to a lesser
degree than for microglia (22.2 
 
  
 
4.8, 29.6 
 
  
 
3.3, and 42 
 
 
 
11.8% inhibition, respectively). To determine which step of
the CDP-choline pathway was blocked by pneumococci,
the distribution of water-soluble choline intermediates was
assessed by thin layer chromatography and quantified by
scintillation counting. Pneumococcal-infected cells accu-
mulated CDP-choline (Fig. 2 C), suggesting that the CPT,
the final step in the pathway, was inhibited.
 
Lyso-Phosphatidylcholine (lyso-PC) Prevents Pneumococcal
Apoptosis in Microglia and Neurons.
 
To determine whether
the inhibition of PtdCho synthesis was causative or second-
ary to induction of a known apoptotic pathway, lyso-PC
was added to the infected cells to bypass the defect in the
CDP-choline pathway (28) by direct acylation to PtdCho
(29). Bacterial growth was unaffected by treatment with
lyso-PC under tissue culture conditions and concentrations
of lyso-PC up to 80 
 
 M showed no toxicity to human cells
(Fig. 3 B). The addition of 80  M lyso-PC to the culture
medium before infection significantly prevented apoptosis
as compared with the untreated infected cells (Fig. 3 A).
Lower doses were less effective. AIF was released from mi-
tochondria in pneumococcal-infected cells and this effect
was blocked by lyso-PC or the calcium chelator, BAPTA-
AM (Fig. 3 B).
Role of Bacterial Factors in Inhibition of PtdCho Biosynthesis.
Inhibition of PtdCho biosynthesis was lost upon challenge
of host cells with heat-killed or antibiotic-treated bacteria
(Fig. 4 A). Bacterial adherence to the target cells mediated
by the major adhesin CbpA was not required (Fig. 4 A). Ex-
posure to a filtered pneumococcal lysate from 108 bacteria/
ml strongly inhibited PtdCho incorporation, suggesting a
product of active bacterial metabolism. This was supported
by testing pure H2O2 and pneumolysin, a pore-forming
toxin, both of which are secreted by pneumococci and are
known to induce apoptosis in host cells (7, 8). Attenuation
of H2O2 production by mutation of pyruvate oxidase, spxB,
or deletion of pneumolysin, plnA, significantly reduced the
ability of pneumococci to cause cell death and inhibit host
Figure 3. Rescue of microglia from apoptosis by lyso-PC. (A) LDH
release and trypan blue uptake of microglia incubated with different con-
centrations of lyso-PC. Microglia were exposed to different concentrations of
lyso-PC for 4 h or to 0.5% Triton X-100 for 30 min and release of LDH
(white bars; reference 49) and uptake of trypan blue (gray bars) were mea-
sured. Values are mean   SEM of 12 experiments (LDH assay) and 6
experiments (trypan blue assay), and the mean of the cells treated with 80
 M lyso-PC was compared with the cells treated with 120 and 160  M
lyso-PC, or 0.5% Triton X-100, respectively. * and #, P   0.05. (B) 5  
105–106 microglia were exposed to 80  M lyso-PC 1 h before infection
with strain D39 or R6 for 4 h. Cells were considered viable according to
their scatter characteristics and their lack of annexin V and/or annexin
V/propidium iodide staining. Values are mean   SE of six duplicate ex-
periments counting 10,000 events. *, P   0.05 with versus without treat-
ment. Inset: Morphology by light microscopy (magnification, 400). (C)
Immunoblot of AIF in mitochondrial and cytosolic cell fractions. Microg-
lia were either uninfected (lane 1) or infected with R6   pretreatment
with 80  M Lyso-PC (lanes 2 and 3) or 5  M BAPTA (lane 4).
Figure 4. Effect of loss of function mutations in S. pneumoniae on ability to
induce apoptosis and inhibit PtdCho synthesis. Microglia were exposed
for 4 h to 107 CFU/ml of each bacterial mutant indicated or to 1  g purified
pneumolysin or 1 mM hydrogen peroxide. [methyl-3H]choline incorporation
was quantitated by scintillation counting. Values are mean   SE of six
experiments and were compared with mean of control, untreated cells
(50,764 cpm/mg protein   100%). Apoptosis was determined as described
in Fig 2 A. *, P   0.05.Zweigner et al. 103
PtdCho synthesis (Fig. 4 B). Infection with plnA, spxB, or
the spxB/plnA double mutant strains caused less inhibition
of PtdCho synthesis, with [methyl-3H]choline incorporation
into PtdCho increasing to 57.8, 77.9, and 92.4%, respec-
tively, compared with uninfected control cells (Fig. 4, A
and B). Addition of either H2O2 or pneumolysin in concen-
trations comparable to 108 bacteria to the host cell culture
significantly inhibited PtdCho synthesis (Fig. 4 A) and in-
duced apoptosis. The precise mechanism of inhibition of
PtdCho biosynthesis by pneumolysin and H2O2  is not
known. Cells treated for 1 h with lyso-PC before exposure
to either toxin were protected from apoptosis (75   17%
apoptotic cells with pneumolysin alone vs. 32   5% pneu-
molysin plus lyso-PC; 95   3% apoptotic cells with H2O2
alone vs. 40   4% H2O2 plus lyso-PC; baseline 4   1%
with no treatment or 5   2% lyso-PC alone).
Role of Host-derived Factors in Inhibition of PtdCho Biosyn-
thesis. Several pathways have been suggested to mediate
apoptosis in response to inhibition of PtdCho biosynthesis.
To rule out accumulation of ceramides as an underlying
mechanism (14), we treated microglia with fumonisin B1, a
natural inhibitor of ceramide synthase that blocks cer-
amide-induced apoptosis (Fig. 5; reference 30). Pretreating
the cells with fumonisin B1 failed to restore PtdCho bio-
synthesis (34.8   11.8% inhibition) or prevent apoptosis in
pneumococcal-challenged cells. Caspase activation is also
known to occur in apoptosis induced by choline starvation
(31), farnesol (32), and in pneumococcal-induced apoptosis
of hippocampal neurons (6). Yet, inhibition of caspase ac-
tivity by ZVAD, which partially decreased apoptosis (from
55   3 to 42   1%), did not prevent inhibition of PtdCho
biosynthesis (55.3   8.3% inhibition). Release of mito-
chondrial AIF accompanied by increased intracellular Ca2 
represents another pathway of pneumococcal-induced apop-
tosis (8), but incorporation of label into PtdCho was still
inhibited in infected cells treated with BAPTA-AM (53.6  
2.1% inhibition). Ca2 -dependent activation of calpains can
cause proteolytic inactivation of the CCT (33). However,
exposure to the calpain inhibitor ALLN before the pneu-
mococcal infection did not rescue PtdCho biosynthesis
(62.1   4.8% inhibition). These data place the inhibition of
PtdCho synthesis independent of the indicated inciting ele-
ments of the apoptotic cascade.
Citicoline Treatment Protects from Pneumococcal-induced Apop-
tosis in the Hippocampus In Vivo. CDP-choline provides pro-
tection against neuronal death caused by decreased phos-
pholipid biosynthesis after cerebral ischemia (34, 35).
Administration of CDP-choline increases cytidine (or uri-
Figure 5. Effect of inhibition of apoptotic pathways on PtdCho synthesis
inhibition by S. pneumoniae. Microglia were treated with the indicated inhib-
itor and then exposed to bacteria for 4 h. [methyl-3H]choline incorporation
was quantified by scintillation counting and apoptosis was determined by
annexin V labeling. Values were compared with control, untreated cells
(29,221 dpm/mg protein    100%). ZVAD, Z-Val_Ala_Asp(Ome)-Fmk;
ALLN, N-acetyl-Leu-Leu-NLE-CHO; BAPTA, Ca2- chelator. *, P   0.05
comparing inhibition of labeling in infected cells plus inhibitor to control cells
plus inhibitor. There is no significant difference between values shown and
infected cells without inhibitor.
Figure 6. Protection from pneumococcal-induced
apoptosis in the hippocampus in vivo. Three groups of six
mice were injected via lumbar puncture with saline or
pneumococci as indicated. One group also received citi-
coline intraperitoneally 24 h before infection and via lumbar
puncture at the time of infection. Mean bacterial number in
cerebrospinal fluid for infected animals was 107 bacteria/ml
for pneumococci alone and 3   107 bacterial/ml for pneu-
mococci with citicoline. Histopathology of the dentate gyrus:
(A) normal control, (B) infected with pneumococcus, and
(C) infected with pneumococcus and treated with citi-
coline. (D) Number of apoptotic neurons per mm2 in the
hippocampus ascertained at 24 h of infection. The data
were statistically analyzed by a One Way Analysis of Variance
(P   0.05) followed by a Student-Newman-Keuls test. #,
the difference between controls and meningitis (P   0.01).
*, the difference between untreated meningitis and citi-
coline treatment (P   0.02).Pneumococcal-induced Inhibition of Phosphatidylcholine Synthesis 104
dine) and choline levels in rodent and human tissues (36,
37), rescues CA1 hippocampal neurons from ischemic
death (38), and increases PtdCho formation in neuronal tis-
sues in vitro and in vivo (39). Our in vitro results suggested
that application of excess CDP-choline might also rescue
PtdCho production in cells dying during pneumococcal
meningitis by overcoming the partial inhibition of CPT.
Treatment of microglia or primary neurons with 100  M
citicoline (CDP-choline) 24 h before exposure to strain R6
rescued the cells from apoptosis. Although media alone or
with citicoline caused little cell death ( 10%), microglia
exposed to R6 for 2 h showed 52   15% apoptosis and this
value was reduced to 16   3% in the presence of citicoline
(n   4; P   0.05). Similarly for primary neurons, exposure
to R6 for 3 h caused 40   12% apoptosis and this value
was reduced to 28   16% in the presence of citicoline
(control baseline 22   7% apoptosis; n   4–8; P   0.05).
Citicoline prevention of pneumococcal-induced apopto-
sis was extended to the in vivo setting using a mouse model
of meningitis (21). Animals were treated with citicoline and
24 h later, they were treated again and challenged with
strain D39 pneumococci. The amount of apoptosis in the
hippocampus was quantitated 24 h after infection. Animals
receiving citicoline had a dramatic reduction in neuronal
cell death (Fig. 6) as compared with untreated, infected
controls (P   0.05). The damage was reduced to levels
found in uninfected controls. This degree of protection has
not been achieved by other apoptosis inhibitors directed at
either the caspase-dependent (6) or -independent pathways
of pneumococcal-induced apoptosis (7). To determine if
apoptosis could be prevented after the onset of infection, as
would be applicable to the clinical situation, mice were
challenged with bacteria and then treated with citicoline
6 h later. Brain histopathology was examined at 24 h. Al-
though all infected mice harbored 3–9   107 bacteria/ml
cerebrospinal fluid, cells in the hippocampus of mice re-
ceiving citicoline were protected against apoptosis to levels
approximating uninfected controls (apoptotic cells/mm2
dentate gyrus: saline controls: 37   18; infected: 71   29;
infected plus citicoline: 39   8; P   0.04).
Discussion
PtdCho is a major component of eukaryotic but not
prokaryotic membranes. We demonstrate for the first time
that a bacterium can inhibit the de novo synthesis of Ptd-
Cho in human cells. Significantly, this inhibition triggers
apoptosis. Although inhibition of PtdCho biosynthesis ini-
tiates apoptosis in cells exposed to xenobiotics (13–15, 17,
28), in mutant cells with genetic CCT dysfunction (40), or
in nutritional choline deprivation (18, 31), the response of
human cells to pneumococcus is the first case where this
mechanism plays a critical role in pathogenesis.
In the brain, PtdCho has an additional role as a precursor
for the biosynthesis of the important neurotransmitter ace-
tylcholine. It is unlikely that acetylcholine deprivation ac-
counts for the observed pneumococcal-induced neuronal
cell death because a low level of acetylcholine is not known
to be a death signal and PtdCho serves as a reservoir of cho-
line for acetylcholine biosynthesis under conditions of nutri-
tional choline deprivation (41). Furthermore, inhibition of
PtdCho biosynthesis and apoptosis were observed in non-
neuronal cells that do not synthesize or secrete acetylcholine.
The membranes of most bacteria are comprised of phos-
phatidylethanolamine and phosphatidylglycerol rather than
the PtdCho that dominates eukaryotic cell membranes (42).
Thus, although respiratory pathogens add choline to a vari-
ety of constituents on their surfaces, they do not incorporate
choline into PtdCho (43). Rather, the pneumococcal licD
genes (44, 45), the bacterial equivalents of the mammalian
CPT, transfer CDP-choline to teichoic acid. There is no
homology between the CPT enzymes of mammals and of
S. pneumoniae, thus explaining the selective inhibition of the
mammalian enzyme by the bacterial toxin(s). The apoptosis
detected in pneumococcal-infected human cells was not
caused by consumption of PtdCho or precursors by pneu-
mococci with resultant starvation of human cells because a
pneumococcal lysate and purified pneumococcal toxins also
induced inhibition of PtdCho biosynthesis and apoptosis.
Interference with caspase activation, calpain activation,
or AIF translocation did not restore synthesis of PtdCho in
pneumococcal-infected cells. This suggests that inhibition
of PtdCho synthesis in this setting is triggered indepen-
dently of the well-known biochemical and cellular events
associated with apoptosis. Purified pneumolysin and H2O2
strongly inhibited PtdCho synthesis. Pneumococcus is
unique among meningeal pathogens for its lack of catalase
and thus, it produces substantial amounts of H2O2. The
mode of H2O2 inhibition of PtdCho synthesis needs to be
further elucidated to determine whether lipid peroxidation
or inhibition of CPT by intracellular acidification (15) oc-
curs. Pneumolysin is well-known to bind to cholesterol in
membranes, oligomerize into ring-shaped assemblies, and
form pores within the lipid bilayer (46). One can hypothe-
size that pneumolysin-induced destabilization of the cell
membrane inhibits the enzymes CPT or CCT because
their substrate binding and enzymatic activities are depen-
dent on the biophysical properties of the bilayer (12).
Exogenous lyso-PC is taken up into cells in a linear fash-
ion for 24 h and converted to PtdCho almost immediately
after cell association (13). 70–80% of the exogenous lyso-
PC in the medium is incorporated into cells. The newly
formed PtdCho is converted to phosphatidylethanolamine
until a final equilibrium ratio of  50% PtdCho and 50%
phosphatidylethanolamine is reached. A significant portion
of the newly formed PtdCho is degraded to either glycero-
phosphocholine or phosphocholine. As the amount of ex-
ogenous lyso-PC increases, the proportion of glycerophos-
phocholine also increases in normal cultured cells and is
released to the medium. Lyso-PC must be added at 24-h in-
tervals to replenish the medium (27), an effect consistent
with repeated dosing to achieve protection in this study.
PtdCho biosynthesis plays a crucial role in proliferating
and resting neuronal cells of the hippocampus (31), a factZweigner et al. 105
that may explain, in part, the very high sensitivity of this re-
gion of the brain to injury during meningitis. Treatment
with excess of the pathway intermediate CDP-choline (citi-
coline) has shown beneficial effects in a number of central
nervous system injury models and pathological conditions of
the brain (35, 38, 39), although the results of human clinical
trials in stroke remain mixed (34). Our data show that neu-
ronal apoptosis after experimental S. pneumoniae meningitis is
amenable to medical intervention using CDP-choline and/
or its metabolic derivatives. This effect was seen even when
citicoline was administered after the animals were symptom-
atic. The strength of the protective effect is significantly
greater than that seen with apoptosis inhibitors and argues for
further study of citicoline to define its clinical potential in
meningitis. It is likely that the mechanism of the beneficial
effect of CDP-choline is to increase the supply of pathway
intermediates and thereby overcome the bacterial-induced
partial inhibition of CPT, the final, nonrate limiting enzyme
in the pathway. However, in theory, the effect might also be
due to reduced phospholipid destruction through inhibition
of phospholipase activation (47) or arachidonic acid release
(39). It is also possible that clinical benefit might be aided by
replenishing acetylcholine in neurons, although this pool is
very small compared with membrane PtdCho (48).
Pneumococci are known to induce caspase- and AIF-
dependent apoptosis. Yet the process studied here was not
reversible with inhibitors of known apoptotic mediators,
but rather complete rescue from apoptosis was achieved by
the addition of lyso-PC or CDP-choline. These findings
would be consistent with a final common pathway of dam-
age at the membrane level regardless of the original stimu-
lus and thus, a dominant salvage effect of agents preserving
phospholipid integration into membranes. The field of
meningitis research has long sought an agent capable of
protecting neurons from damage during antibiotic treat-
ment of disease. This goal appeared to become less realistic
with the discovery of the multiple apoptotic pathways trig-
gered by pneumococci in neurons. The strong response to
lyso-PC or CDP-choline justifies optimism that despite a
diversity of proapoptotic signals during infection, signifi-
cant neuronal rescue might be achieved by a single thera-
peutic intervention for meningitis in vivo.
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